<VariationArchive VariationID="2426449" VariationName="NC_000017.10:g.(?_46019042)_(46024148_?)del" VariationType="Deletion" Accession="VCV002426449" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1946357" VariationID="2426449">
      <GeneList>
        <Gene Symbol="PNPO" FullName="pyridoxamine 5'-phosphate oxidase" GeneID="55163" HGNC_ID="HGNC:30260" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q21.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="47941571" stop="47949308" display_start="47941571" display_stop="47949308" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="46018888" stop="46026673" display_start="46018888" display_stop="46026673" Strand="+" />
          </Location>
          <OMIM>603287</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000017.10:g.(?_46019042)_(46024148_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q21.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" innerStart="46019042" innerStop="46024148" display_start="46019042" display_stop="46024148" variantLength="5107" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.(?_46019042)_(46024148_?)del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.(?_46019042)_(46024148_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000017.10:g.(?_46019042)_(46024148_?)del AND Pyridoxal phosphate-responsive seizures" Accession="RCV003119890" Version="3">
        <ClassifiedConditionList TraitSetID="1807">
          <ClassifiedCondition DB="MedGen" ID="C1864723">Pyridoxal phosphate-responsive seizures</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-14" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15772097</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24645144</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1807" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5840" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED</ElementValue>
                <XRef Type="MIM" ID="610090" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE</ElementValue>
                <XRef Type="MIM" ID="610090" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pyridoxamine 5-Prime-Phosphate Oxidase Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pyridoxal 5'-phosphate-dependent epilepsy</ElementValue>
                <XRef ID="Pyridoxal+5%27-phosphate-dependent+epilepsy/9199" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pyridoxine-5'-phosphate oxidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pyridoxal phosphate-responsive seizures</ElementValue>
                <XRef ID="MONDO:0012407" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PNPOD</ElementValue>
                <XRef Type="MIM" ID="610090" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000551668" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508374" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514632" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552389" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500548" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000506564" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10730" />
                <XRef ID="10730" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Untreated pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency, characterized by a range of seizure types, is "classic" (i.e., seizure onset in the neonatal period) in about 90% of affected individuals and "late onset" (seizure onset after the neonatal period) in about 10%. In classic PNPO deficiency, seizures (including status epilepticus) often begin on the first day of life and typically before age two weeks. In both classic and late-onset untreated PNPO deficiency, seizure semiology varies from myoclonic to clonic or tonic seizures, and seizures are typically resistant to common anti-seizure medications. Independent of age of onset, seizures respond to life-long treatment with a B6 vitamer: pyridoxal 5'-phosphate (PLP) in about 60% of affected individuals and pyridoxine (PN) in about 40%. About 60% of individuals with PNPO deficiency have developmental impairment, affecting speech, cognition, and behavior; some individuals have neurologic impairment such as muscular hypotonia or dystonia. Severe neurodevelopmental impairment is more likely to occur in individuals with PNPO deficiency who experienced diagnostic delay and prolonged periods of uncontrolled seizures.</Attribute>
                <XRef ID="NBK581452" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">35737815</ID>
                <ID Source="BookShelf">NBK581452</ID>
              </Citation>
              <XRef ID="79096" DB="Orphanet" />
              <XRef ID="C1864723" DB="MedGen" />
              <XRef ID="MONDO:0012407" DB="MONDO" />
              <XRef Type="MIM" ID="610090" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7075393" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_018129.3_17_Deletion (entire coding sequence)|MedGen:C1864723" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003795152" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15772097</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24645144</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with PNPO-related conditions. A gross deletion of the genomic region encompassing the full coding sequence of the PNPO gene has been identified. Loss-of-function variants in PNPO are known to be pathogenic (PMID: 15772097, 24645144). The boundaries of this event are unknown as they extend beyond the assayed region for this gene and therefore may encompass additional genes.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PNPO" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.(?_46019042)_(46024148_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1864723" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7075393" TraitType="Disease" MappingType="XRef" MappingValue="C1864723" MappingRef="MedGen">
        <MedGen CUI="C1864723" Name="Pyridoxal phosphate-responsive seizures" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

